Precision BioSciences, Inc. (DTIL) Stock Forecast
DTIL analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 5 analysts
- Price target
- $29.40 average of analyst targets
- Upside to target
- +409.5% from the latest close
- Next earnings
- November 2, 2026 EPS estimate $-1.02
- 52-week range
- $3.57 – $9.28
DTIL analyst ratings
5 analystsNumber of analysts at each rating.
DTIL price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DTIL earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.89 | −$1.19 | −$0.63 | −$1.84 | +51.6% | 3 |
| Current fiscal year (2026) | −$3.87 | −$4.43 | −$3.03 | −$3.63 | −6.5% | 3 |
| Next fiscal year (2027) | −$1.86 | −$2.17 | −$1.55 | −$3.87 | +51.9% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DTIL revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.4M | $0 | $3.0M | +10,476.9% | 4 |
| Current fiscal year (2026) | $13.5M | $10.8M | $16.3M | −60.7% | 4 |
| Next fiscal year (2027) | $8.9M | $0 | $20.0M | −34.2% | 4 |
DTIL EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DTIL revenue: reported and forecast
DTIL EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.61 | −$0.65 | −$0.65 | −$0.85 | −$0.89 | +45.9% | 1 up · 2 down |
| Current fiscal year (2026) | −$2.17 | −$2.49 | −$2.49 | −$3.73 | −$3.87 | +78.2% | 0 up · 3 down |
| Next fiscal year (2027) | −$1.92 | −$1.89 | −$1.89 | −$1.88 | −$1.86 | −2.9% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DTIL earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DTIL beat in 9 of 12.
What analysts expect from DTIL
5 analysts cover Precision BioSciences; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $29.40, 409.5% above the latest close of $5.77. Analysts expect earnings of −$3.87 per share for 2026, −6.5% from a year earlier. For 2027 the average estimate is −$1.86 per share on revenue of $8.9 million. Precision BioSciences beat the EPS estimate in 9 of the last 12 quarters.
Related: DTIL income statement, DTIL key metrics, DTIL chart. See the DTIL stock overview for the latest quote and news.
DTIL forecast FAQ
What is Precision BioSciences's price target?
The average analyst price target for Precision BioSciences is $29.40, 409.5% above the latest close of $5.77.
Is Precision BioSciences a buy, hold or sell?
Of 5 analysts covering Precision BioSciences, 5 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Precision BioSciences's EPS forecast?
Analysts forecast −$3.87 per share for 2026 (range −$4.43 to −$3.03); for 2027 the estimate is −$1.86.
What is Precision BioSciences's revenue forecast?
The average revenue estimate for 2026 is $13.5 million, growth of −60.7%; for 2027 it is $8.9 million.
When does Precision BioSciences report earnings?
Precision BioSciences is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 before the market opens; the EPS estimate is $-1.02.
Does Precision BioSciences usually beat earnings estimates?
Precision BioSciences reported EPS at or above the analyst estimate in 9 of the last 12 quarters.